

Keyword Index Volume 23 (2014/2015)

adverse events of mAbs	63	hepatitis B vaccine	31
alkaline phosphatase	1	hybridoma	13
antibodies	45		
antibody affinity	1	IgA	7
antibody engineering	37	innovative antibodies	37
antibody library gene	21		
antibody-based therapeutics	63	licensed mAbs and associated challenges	63
antiphospholipid antibodies	27	limiting dilution	7
appendectomy	31		
autoantibodies	27	monoclonal antibody	1, 7, 13,21
autoimmunity	27	multiple sclerosis	31
biomedical students	57	neutralizing antibodies	73
bullous pemphigoid	27	Nigeria	57
cancer immunotherapy	13	passive immunotherapy	49
		pemphigus	27
dissociation constant	1	plants	45
		production	7
Ebola antibody discovery	49		
Ebola virus	49	risk factors	31
edible antibodies	37		
effector functions	49	safety and risks of mAbs	63
ELISA	1, 7	scalable antibody production	37
epidermal growth factor receptor	13	ScFv	73
		secretory IgA	37
FDA approved mAbs	63	Sokoto	57
first-in-plants	37		
		tetanus neurotoxin	73
glycan engineering	45	tetanus toxin	21
glycosylation	45	tonsillectomy	31
Hepatitis B surface antigen	57	Usmanu Danfodiyo University	57